21 CFR Part 820

21 CFR Part 820

Definition

21 CFR Part 820 is now the ISO 13485-aligned Quality Management System Regulation (QMSR). As of February 2, 2026, the FDA has updated 21 CFR Part 820 to incorporate by reference the international standard ISO 13485:2016. The regulation outlines the requirements for the quality systems used in the design, manufacturing, packaging, labeling, storage, installation, distribution, and servicing of medical device products in the United States.

The 21 CFR Part 820 regulation applies to finished medical device products and their components, setting specific requirements that prevent defects before they occur. It covers management responsibility, design controls, production processes, corrective and preventive actions, and complaint handling. All manufacturers of medical devices intended for sale in the United States must comply with this regulation.

Framework

Understanding the 21 CFR Part 820 regulations within the broader regulatory landscape transforms how companies approach medical device quality systems. 21 CFR Part 820 aligns closely with ISO 13485, sharing fundamental principles such as risk-based thinking, process validation, design controls, and systematic documentation. This regulatory alignment creates advantages for companies already certified to ISO 13485.

Complementary Guidelines and Standards

Several supporting frameworks include:

Historical Evolution and Modern Philosophy

Initially introduced in 1996, the regulation shifted from inspection-based quality to prevention-based systems. The 2026 QMSR represents the evolution towards harmonizing with ISO 13485 while maintaining FDA-specific requirements. Emphasis is on risk-based approaches, continuous improvement, and documented evidence of effective quality systems.

Requirements

The requirements under 21 CFR Part 820 are organized around several foundational components:

Management must ensure quality policy, resources, and personnel suitable for quality matters. Extensive documentation is required, including:

Benefits

Implementing compliant quality systems under 21 CFR Part 820 leads to measurable operational impacts including:

Strong quality systems not only enhance regulatory compliance but also provide strategic advantages across the organization by improving R&D, manufacturing, customer service, and supply chain processes.

Use Case

21 CFR Part 820 for Medical Device Manufacturers (Class I, II, and III)

Manufacturers face unique compliance challenges based on device classification, with Class III devices requiring rigorous design controls.

21 CFR Part 820 for Contract Manufacturers (CMOs and CDMOs)

Compliance challenges arise when producing products for multiple clients, necessitating adaptable quality systems.

21 CFR Part 820 for Combination Product Manufacturers

Combination product manufacturers must meet both medical device and pharmaceutical regulations, presenting complex challenges in design controls and process validation.

21 CFR Part 820 for Software as a Medical Device (SaMD) Developers

SaMD developers need systems focused on design controls, configuration management, and software validation.

FAQ

When is the compliance deadline for the 21 CFR Part 820 harmonization with ISO 13485:2016?

Compliance is required as of February 2, 2026.

How should companies prepare for FDA inspections?

Maintain quality systems that demonstrate compliance continuously.

What documentation is required to demonstrate compliance with the Quality System Regulation (QSR)?

Required documents include quality manuals, device master records, and CAPA records.

Can 21 CFR Part 820 requirements change?

Yes, the FDA may update regulations based on new developments.

How can manufacturers prepare for an FDA inspection?

Ensure comprehensive quality system alignment with Part 820 requirements.